A Phase 1b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Prostate Cancer
Age: Between 18 years - 100 years
Gender: Male

Other Inclusion Criteria:

1) Pathologically confirmed metastatic castrate-resistant adenocarcinoma of the prostate with tumor progression while on androgen deprivation therapy with castrate levels of serum testosterone. 2) Life expectancy = 3 months as determined by the investigator.

You may not be eligible for this study if the following are true:

1) Prior treatment with immune checkpoint blockade therapies including anti-cytotoxic Tlymphocyte-associated protein-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies. 2) Prior anticancer treatment for the disease under study, including approved agents, systemic radiotherapy, or investigational therapy, within 4 weeks (or 5 half-lives) prior to initiation of study treatment. 3) Prior allogeneic stem cell or solid organ transplantation.